1-(3-pyridylmethyl)imidazole | 72459-39-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-(3-pyridylmethyl)imidazole
• 英文别名: 3-(1H-imidazol-1-ylmethyl)pyridine；1-(3-Pyridylmethyl)imidazol；3-imidazol-1-ylmethyl-pyridine；3-(1-Imidazolylmethyl)pyridine；3-(imidazol-1-ylmethyl)pyridine
• CAS: 72459-39-3
• 化学式: C₉H₉N₃
• 分子量: 159.191
• InChiKey: IRLWEKCRDMFHQW-UHFFFAOYSA-N

物化性质

• 沸点：
  348.5±17.0 °C(Predicted)
• 密度：
  1.13±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(3-pyridylmethyl)imidazole 在 ammonium hexafluorophosphate 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 96.0h， 生成
  参考文献：
  名称：

  N-Hetercocyclic carbene metallacrown ethers based on 1,8-dihydroxy-9,10-anthraquinone: Synthesis, structures and application in situ palladium-catalyzed Suzuki–Miyaura reaction

  摘要：

  N-Hetercocyclic carbene precursors containing 1,8-dihydroxy-9,10-anthraquinone derivative: 1,8-bis(3-(N-R-imidazole)propoxy)-9,10-anthraquinone 2X (L1H(2): R - PhCH2, X - Br, L3H(2): R - Bu-n, X - PF6, L4H(2): R = PhCH2, X = PF6, L5H(2): R = PyCH2, X = PF6), 1,8-bis(2-(N-R-imidazole) ethoxy)-9,10-anthraquinone 2X (L2H(2): R = PhCH2, X = PF6) and 1,8-bis(3-(N-R-imidazole)propoxy)anthracene 2X (L6H(2): R = PhCH2, X = PF6) were synthesized. N-Heterocyclic carbene metallacrown ethers: L1AgBr (1), L2AgPF(6) (2), L3AgPF(6) (3), L4AgPF(6) (4), L6AgPF(6) (5), L4AuPF(6) (6), L5Hg(PF6)(2) (7) have been prepared. Complexes 1-7 were characterized by elemental analysis, NMR spectroscopy and single crystal X-ray diffraction. Particularly, complex 4 and PdCl2(CH3CN)(2) synergetically and efficiently catalyzed in situ Suzuki-Miyaura cross-coupling reaction in 100% aqua-phase. (C) 2013 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.jorganchem.2013.07.001
• 作为产物：
  描述：

  咪唑 、 alkaline earth salt of/the/ methylsulfuric acid 反应 3.0h， 生成 1-(3-pyridylmethyl)imidazole
  参考文献：
  名称：

  Substituted heteroaromatic compounds: effect on nicotine self-administration in rats

  摘要：

  Certain compounds that nonselectively inhibit a prominent human nicotine-metabolizing enzyme (i.e., human cytochrome P-450 2A6, hCYP 2A6) showed inhibition of smoking in humans. However, a comprehensive examination of hCYP 2A6 inhibitors to decrease nicotine self-administration in rats has not been reported.We tested substituted heteroaromatic compounds designed to selectively inhibit hCYP 2A6 in a model system to (a) examine selective hCYP 2A6 inhibitors to decrease cotinine formation in vivo in rats administered with nicotine and (b) examine their efficacy to decrease nicotine self-administration in rats.Rats were trained to IV self-administer nicotine in 1-h sessions. Nicotine self-administration was carried out at a unit dose of 0.03 mg/kg/infusion in 0.1 ml/s. Pretreatment with substituted heteroaromatic test compounds (0.5-25 mg/kg, i.p., 30 min prior to nicotine self-administration sessions) resulted in dose-dependent decreases of nicotine self-administration. Using operant conditioning techniques, nicotine- vs. food-reinforced responding was evaluated for compounds 10 and 11.Compounds 10 and 11 selectively decreased nicotine self-administration with estimated ED50 values 4 and 2.8 mg/kg, respectively. Of the test compounds examined, none showed significant affinity for mammalian alpha 4 beta 2- or alpha 7-neuronal nicotinic acetylcholine (nAChR) receptors and none were inhibitors of the human dopamine transporter (hDAT); thus, neither the endogenous nAChRs nor DAT apparently plays a role in decreasing nicotine self-administration for this series of compounds.The results indicate that chemical analogs of nicotine can play a role in nicotine self-administration harm reduction but a non-nAChR and a non-hDAT mechanism are likely involved.

  DOI：

  10.1007/s00213-011-2608-6

文献信息

• Optimization of the First Selective Steroid-11β-hydroxylase (CYP11B1) Inhibitors for the Treatment of Cortisol Dependent Diseases
  作者：Ulrike E. Hille、Christina Zimmer、Jörg Haupenthal、Rolf W. Hartmann

  DOI：10.1021/ml100283h

  日期：2011.8.11

  CYP11B1 is the key enzyme in cortisol biosynthesis, and its inhibition with selective compounds is a promising strategy for the treatment of diseases associated with elevated cortisol levels, such as Cushing’s syndrome or metabolic disease. Expanding on a previous study from our group resulting in the first potent and rather selective inhibitor described so far (1, IC50 = 152 nM), we herein describe

  CYP11B1 是皮质醇生物合成的关键酶，它用选择性化合物抑制是治疗与皮质醇水平升高相关的疾病（如库欣综合征或代谢疾病）的有前景的策略。Expanding on a previous study from our group resulting in the first potent and rather selective inhibitor described so far ( 1 , IC 50 = 152 nM), we herein describe further optimizations of the imidazolylmethyl pyridine core. 合成的 42 种物质中有五种化合物的 IC 50值低于 50 nM。最有趣的是naphth-1-yl 化合物23 (IC 50 = 42 nM)，对高度同源的CYP11B2 ( 1：18 倍）以及分别对雄激素和雌激素形成酶
• Flexible, dicationic imidazolium salts for<i>in situ</i>application in palladium-catalysed Mizoroki-Heck coupling of acrylates under aerobic conditions
  作者：Marilyn Daisy Milton、Parul Garg

  DOI：10.1002/aoc.3503

  日期：2016.9

  incorporating the features of both bidentate chelating O,O ligand and carbene, shows the maximum catalytic activity. A variety of aryl and heteroaryl methyl and ethyl cinnamates were synthesized using these imidazolium salts as preligands. In addition, NMR studies confirm in situ generation of normal N‐heterocyclic carbenes from the C‐2 position of imidazol‐2‐ylidene ring. The mercury poisoning test was also

  新的不对称N，N的合成，表征及原位催化性能描述了在好氧条件下丙烯酸酯与芳基溴化物在咪唑罗基-赫克偶联过程中基于二氮杂咪唑的二元盐。合成了一系列具有可变的空间和电子特性的柔性二羧酸盐，收率良好。使用光谱技术可以很好地表征所有盐。X射线衍射分析具有相同的双主链和不同的抗衡阴离子的两种盐表明，配体采用两种不同的构象，这些构象受阴离子的性质影响。因此，配体由于其柔性性质而能够根据环境变化而改变其构象。发现所有合成的咪唑鎓盐均在原位具有活性有氧条件下钯催化的米佐罗基-赫克偶联。在这些盐中，结合了双齿螯合O，O配体和卡宾的特征的羟基官能化咪唑鎓盐显示出最大的催化活性。使用这些咪唑鎓盐作为预配体合成了各种肉桂酸的芳基和杂芳基甲基和乙基酯。此外，NMR研究证实原位生成正常N咪唑-2-亚烷基环的C-2位的杂环卡宾。还进行了汞中毒测试，以确定具有催化活性的钯物质的性质。有氧条件，低催化负载量（0.5 mol％
• Electrostatic Potential Differences and Halogen-Bond Selectivity
  作者：Christer B. Aakeröy、Tharanga K. Wijethunga、John Desper、Marijana Đaković

  DOI：10.1021/acs.cgd.5b01770

  日期：2016.5.4

  kJ/mol, and in all of the co-crystals found herein (7/7), the halogen-bond donor favored the best acceptor site. These results allow us to propose some tentative guidelines and rationales for halogen-bond preferences in competitive systems. If ΔE < 35 kJ/mol, the electrostatic potential difference is not large enough to allow the donor molecules to form halogen bonds of sufficiently different thermodynamic

  通过对9个全氟化卤素键供体和12个对位受体进行系统性共结晶，探讨了基于分子静电势的卤素键相互作用选择性的指南，该两个单体呈现出两个具有不同静电势的结合位点。108个反应中总共89个导致共晶形成（如IR光谱所示），获得了35个新的晶体结构。为了避免在这些实验中出现任何潜在的溶剂-溶质偏差，甲醇专门用作晶体生长的溶剂。根据每种情况下观察到的卤素键连接性的具体性质，将结构分为三个不同的组。每个分子上两个受体位点之间的静电势差定义为ΔE值。第1组包含ΔE值低于35kJ / mol单位的受体分子，并且在该类别中，卤素键发生在所有共晶体（9/9）的两个结合位点上。第2组中的对位受体分子的特征在于ΔE值在35–65 kJ / mol范围内，在该组中，一半的结构显示卤素键与最佳受体（11/22），一半的结构显示卤素键与最佳受体。两个结合位点（11/22）。在第3组中，ΔE值＞ 167kJ / mol，并且
• [EN] SELECTIVE CYP11B1 INHIBITORS FOR THE TREATMENT OF CORTISOL DEPENDENT DISEASES<br/>[FR] INHIBITEURS SÉLECTIFS DE CYP11B1 POUR LE TRAITEMENT DE MALADIES DÉPENDANTES DU CORTISOL
  申请人：UNIV SAARLAND

  公开号：WO2012052540A1

  公开（公告）日：2012-04-26

  The present invention relates to compounds which selectively inhibit CYP11B1. Preferably, the compounds of the present invention do not substantially inhibit CYP11B2. Moreover, the compounds of the present invention do not substantially inhibit CYP17 and/or CYP19, either. Amongst other applications of the compounds of the present invention, they can be used for the treatment of Cushing's syndrome or metabolic disease.

  本发明涉及选择性抑制CYP11B1的化合物。优选，本发明的化合物不显著抑制CYP11B2。此外，本发明的化合物也不显著抑制CYP17和/或CYP19。在本发明的化合物的其他应用中，它们可用于治疗库欣综合症或代谢性疾病。
• SELECTIVE CYP11B1 INHIBITORS FOR THE TREATMENT OF CORTISOL DEPENDENT DISEASES
  申请人：Hartmann Rolf

  公开号：US20140155407A1

  公开（公告）日：2014-06-05

  The present invention relates to compounds which selectively inhibit CYP11B1. Preferably, the compounds of the present invention do not substantially inhibit CYP11B2. Moreover, the compounds of the present invention do not substantially inhibit CYP17 and/or CYP19, either. Amongst other applications of the compounds of the present invention, they can be used for the treatment of Cushing's syndrome or metabolic disease.

  本发明涉及一种选择性抑制CYP11B1的化合物。优选地，本发明的化合物不会显著抑制CYP11B2。此外，本发明的化合物也不会显著抑制CYP17和/或CYP19。在本发明化合物的其他应用中，它们可用于治疗库欣综合征或代谢疾病。